StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research note released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Performance

Shares of NYSE SENS opened at $0.34 on Wednesday. The company has a market cap of $179.17 million, a PE ratio of -2.41 and a beta of 0.79. Senseonics has a 12 month low of $0.32 and a 12 month high of $0.75. The company has a debt-to-equity ratio of 59.17, a current ratio of 3.11 and a quick ratio of 2.89. The company has a 50-day simple moving average of $0.37 and a 200-day simple moving average of $0.41.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. On average, equities analysts anticipate that Senseonics will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Senseonics

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Senseonics during the first quarter valued at approximately $162,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after buying an additional 211,128 shares in the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Senseonics during the first quarter valued at approximately $91,000. Vanguard Group Inc. lifted its position in Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.